Surabhi Dangi-Garimella, PhD

The CDC's Morbidity and Mortality Weekly Report recommends that Medicaid expansion states should direct more attention to smoking cessation programs to improve access and raise awareness about these programs among beneficiaries and providers.

Two names are being floated as likely replacements for the current FDA commissioner: Scott Gottlieb, MD, a resident scholar with the American Enterprise Institute, and Jim O’Neill, a managing director at Mithril Capital, a global investment firm.

A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Research from the Dana-Farber Cancer Institute and the Broad Institute, published in Nature, has identified genomic changes that could explain the development of testicular cancer and why this disease is more responsive to chemotherapy.

Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.

Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.

The House Energy and Commerce Committee's subcommittee on health will gather testimonial from leaders of the US Preventive Services Task Force, the American Academy of Family Physicians, and the American Urologic Association, on a bill called H.R. 1151.

A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.

The American Society of Clinical Oncology (ASCO) has released the Criteria for High-Quality Clinical Pathways in Oncology, which is expected to help providers assess the quality, utility, and integrity of pathway programs in the United States.

With $372 million carved out for the National Institutes of Health innovation account in 2017, and about $114 million assigned to President Barack Obama’s Precision Medicine Initiative for the fiscal year 2018, the 21st Century Cures Act has a lot at stake for healthcare in the United States.

Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology Care® meeting had in store for its attendees.

At the 5th annual Patient-Centered Oncology Care® meeting in Baltimore, Maryland, moderator Bruce Feinberg, DO, was joined by a care provider, a payer, and a community oncology representative to discuss efforts that maintain the patient at the core of payment models.

At the 5th annual Patient-Centered Oncology Care® meeting, Roy Beveridge, MD, senior vice president and chief medical officer at Humana, walked the audience through the healthcare world’s transition to value-based care and explained why payers have faith in this transition.

A prospective trial that reached out to patients with cirrhosis to undergo an ultrasound screen found that the outreach effort doubled the percentage of patients who were screened for hepatocellular carcinoma.

At the 5th annual meeting of Patient-Centered Oncology Care®, hosted by The American Journal of Managed Care, November 17-18 in Baltimore, Maryland, experts with diverse experiences and backgrounds discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia.

A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase.

A hospital in China has made history by injecting a patient with lung cancer with revolutionary, yet controversial, CRISPR-Cas9—edited T cells. The first patient was injected on October 28.

Amgen and Allergan have announced that they have submitted a Biologics License Application (BLA) for ABP 215, a biosimilar to bevacizumab (Avastin).

A new study conducted at the Massachusetts General Hospital evaluated the impact of intraoperative radiotherapy (IORT), along with induction chemotherapy and chemo-radiotherapy, in patients with advanced disease, and observed hints of success.

A prospective trial among breast cancer patients enrolled in The Pathways Study has found that higher levels of vitamin D can lower the risk of breast cancer morbidity and mortality.

A study conducted in Australia has concluded that a person’s inherited risk factors for melanoma should be considered when developing self-examination and surveillance programs.

Will Vice President Joe Biden's Cancer Moonshot initiative be able to sustain it's momentum in 2017 following the transition in government?